These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27380317)

  • 41. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice.
    Hanson BJ; Boon AC; Lim AP; Webb A; Ooi EE; Webby RJ
    Respir Res; 2006 Oct; 7(1):126. PubMed ID: 17040574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
    Reece PA
    Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
    Baras B; Stittelaar KJ; Kuiken T; Jacob V; Bernhard R; Giannini S; de Waal L; van Amerongen G; Simon JH; Osterhaus AD; Hanon E; Mossman SP
    Vaccine; 2011 Mar; 29(11):2092-9. PubMed ID: 21237275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuropathology of H5N1 virus infection in ferrets.
    Peng BH; Yun N; Chumakova O; Zacks M; Campbell G; Smith J; Smith J; Linde S; Linde J; Paessler S
    Vet Microbiol; 2012 May; 156(3-4):294-304. PubMed ID: 22176758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice.
    Galabov AS; Simeonova L; Gegova G
    Antivir Chem Chemother; 2006; 17(5):251-8. PubMed ID: 17176629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Highly pathogenic avian influenza A virus (H5N1) can be transmitted in ferrets by transfusion.
    Wang X; Tan J; Zhao J; Ye Z; Hewlett I
    BMC Infect Dis; 2014 Apr; 14():192. PubMed ID: 24712669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
    Beale DJ; Oh DY; Karpe AV; Tai C; Dunn MS; Tilmanis D; Palombo EA; Hurt AC
    Metabolomics; 2019 Mar; 15(3):33. PubMed ID: 30830484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
    Marathe BM; Wong SS; Vogel P; Garcia-Alcalde F; Webster RG; Webby RJ; Najera I; Govorkova EA
    Sci Rep; 2016 May; 6():26742. PubMed ID: 27221530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An addition to treatment options for avian influenza A H5N1?
    Baz M; Subbarao K
    Lancet Infect Dis; 2015 Mar; 15(3):251-3. PubMed ID: 25662593
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)].
    Loginova SIa; Borisevich SV; Shkliaeva OM; Maksimov VA; Bondarev VP; Nebol'sin VE
    Antibiot Khimioter; 2010; 55(7-8):10-2. PubMed ID: 21140557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1).
    Adisasmito W; Chan PK; Lee N; Oner AF; Gasimov V; Zaman M; Bamgboye E; Dogan N; Starzyk K; Dreyer NA; Toovey S
    J Infect Dis; 2011 Sep; 204(5):810-1. PubMed ID: 21844308
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005-2008.
    Soepandi PZ; Burhan E; Mangunnegoro H; Nawas A; Aditama TY; Partakusuma L; Isbaniah F; Ikhsan M; Swidarmoko B; Sutiyoso A; Malik S; Benamore R; Baird JK; Taylor WR
    Chest; 2010 Sep; 138(3):665-73. PubMed ID: 20507944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between oseltamivir and herbal medicines used for treating avian influenza.
    Yang MS; Law FC; Wong RN; Mak NK; Wei XY
    Hong Kong Med J; 2012 Dec; 18 Suppl 6():34-6. PubMed ID: 23249852
    [No Abstract]   [Full Text] [Related]  

  • 54. Local and systemic immunity to influenza infections in ferrets.
    Barber WH; Small PA
    Infect Immun; 1978 Jul; 21(1):221-8. PubMed ID: 711316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influenza A H5N1 and HIV co-infection: case report.
    Fox A; Horby P; Ha NH; Hoa le NM; Lam NT; Simmons C; Farrar J; Van Kinh N; Wertheim H
    BMC Infect Dis; 2010 Jun; 10():167. PubMed ID: 20540811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
    Luke TC; Kilbane EM; Jackson JL; Hoffman SL
    Ann Intern Med; 2006 Oct; 145(8):599-609. PubMed ID: 16940336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood products for Spanish influenza: a future H5N1 treatment?
    Logtenberg SJ; Bilo HJ
    Ann Intern Med; 2007 May; 146(9):686-7; author reply 687. PubMed ID: 17470841
    [No Abstract]   [Full Text] [Related]  

  • 58. Adjunctive therapies and immunomodulatory agents in the management of severe influenza.
    Hui DS; Lee N; Chan PK
    Antiviral Res; 2013 Jun; 98(3):410-6. PubMed ID: 23578727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of intravenous immunoglobulin preparations against viral and bacterial infections in mouse protection tests.
    Stephan W; Dichtelmüller H
    Infection; 1983; 11(4):227-31. PubMed ID: 6618678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of Ergoferon versus oseltamivir: Reply to the Letter to the Editor.
    Andrianova E; Putilovskiy M
    Int J Infect Dis; 2019 Dec; 89():190-192. PubMed ID: 31626982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.